Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants
Active, not recruiting
Study Details
Medical Condition
Study Phase
Intervention Type
Product
DateMedical ConditionRequirement Information
Date
AgeDateParticipation Requirements
Inclusion Criteria
Exclusion CriteriaInclusion CriteriaThe primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.
| Location | Status |
|---|---|
Location United Kingdom Research Site Harrow, United Kingdom, HA1 3UJ | Status Not Available |
